Evidence map›Paper›PMID 37736702›Full record

ArticleACR open rheumatology2023

Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA Trial.

Maja Skov Kragsnaes, Jesus Miguens Blanco, Benjamin H Mullish, Jose Ivan Serrano-Contreras, Jens Kjeldsen, Hans Christian Horn, Jens Kristian Pedersen, Heidi Lausten Munk, Anna Christine Nilsson, Ash Salam and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACR open rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Maja Skov KragsnaesOdense University Hospital and University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0001-9641-9065
Jesus Miguens BlancoImperial College London, London, UK.
Benjamin H MullishImperial College London and St. Mary's Hospital, Imperial College Healthcare National Health Service Trust, London, UK.ORCID https://orcid.org/0000-0001-6300-3100
Jose Ivan Serrano-ContrerasImperial College London, London, UK.
Jens KjeldsenOdense University Hospital and University of Southern Denmark, Odense, Denmark.
Hans Christian HornOdense University Hospital, Odense, Denmark.
Jens Kristian PedersenOdense University Hospital and University of Southern Denmark, Odense, Denmark.
Heidi Lausten MunkOdense University Hospital, Odense, and Rigshospitalet, Copenhagen, Denmark.
Anna Christine NilssonOdense University Hospital, Odense, Denmark.
Ash SalamImperial College London, Hammersmith Hospital Campus, London, UK.
Matthew R LewisImperial College London, Hammersmith Hospital Campus, London, UK.
Elena ChekmenevaImperial College London, Hammersmith Hospital Campus, London, UK.
Karsten KristiansenUniversity of Copenhagen, Copenhagen, Denmark, and Institute of Metagenomics, Qingdao-Europe Advanced Institute for Life Sciences, Qingdao, China.
Julian R MarchesiImperial College London, London, UK.
Torkell EllingsenOdense University Hospital and University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0003-0426-4962
National Health Service · GBUniversity of Southern Denmark · DKUniversity of Copenhagen · DK

Funding

Versus Arthritis 21228
6 · The paper itself

Abstract

objectiveWe investigated intestinal permeability and fecal, plasma, and urine metabolomic profiles in methotrexate-treated active psoriatic arthritis (PsA) and how this related to clinical response following one sham or fecal microbiota transplantation (FMT).

methodsThis exploratory study is based on the FLORA trial cohort, in which 31 patients with moderate-to-high peripheral PsA disease activity, despite at least 3 months of methotrexate-treatment, were included in a 26-week, double-blind, 1:1 randomized, sham-controlled trial. Participants were randomly allocated to receive either one healthy donor FMT (n = 15) or sham (n = 16) via gastroscopy. The primary trial end point was the proportion of treatment failures through 26 weeks. We performed a lactulose-to-mannitol ratio (LMR) test at baseline (n = 31) and at week 26 (n = 26) to assess small intestinal permeability. Metabolomic profiles in fecal, plasma, and urine samples collected at baseline, weeks 4, 12, and 26 were measured using

resultsTrial failures (n = 7) had significantly higher LMR compared with responders (n = 19) at week 26 (0.027 [0.017-0.33]) vs. 0.012 [0-0.064], P = 0.013), indicating increased intestinal permeability. Multivariate analysis revealed a significant model for responders (n = 19) versus failures (n = 12) at all time points based on their fecal (P < 0.0001) and plasma (P = 0.005) metabolomic profiles, whereas urine metabolomic profiles did not differ between groups (P = 1). Fecal N-acetyl glycoprotein GlycA correlated with Health Assessment Questionnaire Disability Index (coefficient = 0.50; P = 0.03) and fecal propionate correlated with American College of Rheumatology 20 response at week 26 (coefficient = 27, P = 0.02).

conclusionIntestinal permeability and fecal and plasma metabolomic profiles of patients with PsA were associated with the primary clinical trial end point, failure versus responder.

Identifiers

PMID37736702
PMCPMC10642255
OpenAlexW4386944429

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.